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I.

INTRODUCTION: #SAVEJOSH

Aimee Hardy, a mother from a small town in Virginia, probably never
intended to become the symbol of a new era of medical decision making or
the center of a bioethical debate.1 Her seven-year-old son, Josh, who had
battled cancer since he was only a few months old, was dying.2
Conventional methods to save him had been unsuccessful and it seemed
that the only chance for Josh rested in an experimental drug known as
Brincidofovir that was in early stages of testing.3 Josh had not been eligible
for those early tests and letters from Josh’s medical team to Chimerix, the
company that made the drug, had not convinced Chimerix to provide
Brincidofivir through a process known as “compassionate use.”4
Compassionate use, also known as expanded access, allows patients who
have been approved by the Food and Drug Administration (“FDA”) to
request that companies provide them with an investigational pharmaceutical
product that has not yet been approved for general distribution.5 On March
6, 2014 Aimee Hardy turned to Facebook and wrote a post seeking anyone
who could influence Chimerix to change their mind.6 In the Internet age,
where everything is transmitted almost instantly, movements are often

1. See Ariana Eunjung Cha, Crowdsourcing Medical Decisions: Ethicists Worry Josh Hardy
Case May Set Bad Precedent, WASH. POST, Mar. 23, 2014 (reporting on some of the ethical
concerns raised by this particular instance of compassionate use). See also Arthur Caplan &
Kenneth Moch, Rescue Me: The Challenge of Compassionate Use in the Social Media Era,
HEALTH AFFAIRS, Aug. 27, 2014 (providing an overview of the specific events surrounding the
campaign to get the necessary drug for Josh).
2. See Caplan & Moch, supra note 1 (noting that Josh had a deadly infection because of a
bone marrow stem cell transplant, which was required because of the various types of cancer he
had been battling since he was nine months old, that left his immune system compromised).
3. See David Kroll, Rescuing Compassionate Use From Social Media and Death Threats,
FORBES, Aug. 27, 2014 (detailing how doctors had already tried the usual “drug of choice,”
cidofovir, to fight Josh’s infection, but repeated use had not improved his condition and was
damaging his kidneys).
4. See Caplan & Moch, supra note 1 (recounting how St. Jude Children Hospital sent two
letters, including one from the Vice President of Clinical Trials Administration, yet both requests
were denied).
5. See Alexander Gaffney, Regulatory Explainer: FDA’s Expanded Access (Compassionate
Use) Program, REG. AFFAIRS PROF. SOC’Y (Feb. 4, 2014) (providing a concise overview of the
compassionate use program). See also Vicki Brower, Food and Drug Administration Responds to
Pressure for Expanded Drug Access, 106 J. NAT’L CANCER INST. 1 (2014) (noting that the FDA
officially refers to this process as expanded access, and that compassionate use is a colloquial
term). For the purposes of this paper, I will use the terms interchangeably.
6. See Caplan & Moch, supra note 1.
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distilled down to a succinct phrase encapsulated in a hashtag. This was the
humble beginning of #SaveJosh.7
Over a few days, what started as a plea to friends evolved into a
massive campaign with media coverage on every major outlet.8 Pictures of
Josh, first showing him appearing healthy and smiling, often standing
outside wearing his favorite baseball hat, were juxtaposed against pictures
of him in a hospital bed, connected to tubes, clearly sick.9 The headlines
were damning for the company.10 CNN reported “Company denies drug to
dying child” and included footage of Josh in the hospital.11 Huffington Post
published a blog titled: “A Cancer Drug Could Save This 7-Year-Old, But
the Company Behind it Won’t Give Him Access.”12 It was a situation that
resonated with thousands of people who signed online petitions, called the
company, and sent letters and emails.13 On March 12, 120 hours after the
initial post, Chimerix announced that they had worked with the FDA to
create a new clinical trial for Brincidofivir that would include Josh.14 Soon
after Josh received the medicine, he started to recover.15 A year later his
mom still updates the “SaveJosh” Facebook page, with its nearly 30,000
followers, with pictures of the little boy, not fully healthy, but alive with his
loving family.16
This is the type of story seemingly everyone can get behind: a
compassionless company brought back in line with humanity at the urging
7. See id. (mentioning that Josh’s uncle was the first to use the #SaveJosh tag by creating
both a Facebook and a Twitter page the same day that Aimee Hardy posted her request to
Facebook).
8. See Elizabeth Cohen, Company Denies Drug to Dying Child, CNN, Mar. 11, 2014; see
also Jay Scott, A Cancer Drug Could Save This 7-Year Old, But the Company Behind It Won’t
Give Him Access, HUFFINGTON POST, Mar. 12, 2014.
9. Cohen, supra note 8.
10. Social Media Shakes FDA’s Power: A Case Study of Compassionate Use, NAT’L CTR.
FOR POL’Y ANAL. (Sept. 2, 2014), http://healthblog.ncpa.org/social-media-shakes-fdas-power-acase-study-of-compassionate-use/ (stating that Chimerix received “such vilification” that the
company was motivated to find a solution to get the drug to Josh).
11. Cohen, supra note 8.
12. See Scott, supra note 8.
13. See Cha, supra note 1 (detailing how, among the various forms of support people
provided for Josh, 20,000 people signed a petition in support of him and even celebrities retweeted
the #SaveJosh hashtag). See also Caplan & Moch, supra note 1 (noting that #SaveJosh twitter feed
was amongst the top five national stories on that platform and over one million people had viewed
the Facebook page in just four days).
14. See Caplan & Moch, supra note 1.
15. See Marc Dresner, Social Media “Compassionate Use” Crusade Sets Unsettling
Precedent,
P’SHIPS
IN
CLINICAL
TRIALS
(Jan.
15,
2015),
http://www.clinicaltrialpartnershipsblog.com/2015/01/compassionate-use-social-mediacrusade.html (asserting that the drug saved Josh’s life and that his condition “dramatically
improved”).
16. Aimee Hardy, SaveJosh (Mar. 12, 2015), https://www.facebook.com/SaveJoshHardy.
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of thousands of kind strangers motivated only by a sense of justice and
desire to help out a family, who in this case, got their happy ending. In fact,
after the announcement, Chimerix stock increased nearly fifty percent.17 As
the story faded from the headlines, the casual reader might think that this
was a win for all the parties involved.18 But was it? And even if it was, did
this spark a revolution with the potential for serious and unintended
consequences?
In this paper, I argue that the story of Josh Hardy and other instances
where medicine and new technology collide are emblematic of a revolution
in medical decision-making driven by crowdsourcing, direct-to-consumer
(“DTC”) products, and apomediation.19 However, as with most revolutions,
these changes come with a cost. Despite the allure of medical breakthroughs
and life-saving technology, there are serious risks that have yet to be fully
addressed by all of the stakeholders in the medical community.20 First,
research and observation indicates that not every population can access
these new technologies, and the breakdown often occurs along traditional
divides, such as race and socioeconomic status.21 The medical, ethical, and
legal community must consider issues of social justice in order to ensure
that minority groups have the opportunity to participate in and benefit from
these changes. Second, the limited availability and high expense of the
medical products involved mean that the medical community must deal
with the difficulties of allocating finite resources.22 Third, technology is
dramatically altering the nature of doctor-patient relationships, which could
impact the quality of care.23 Finally, researchers and consumers should
question the validity and quality of the products that result from new
technologies.24
Technological advances in medicine, even those with risks associated
with them, are unavoidable. I will propose several ways that society can
embrace some of the benefits of new technology while addressing the
variety of ethical issues raised.25 In some cases, medicine should be able to
harness new technology, like DTC products, to advance research, and
ultimately improve the quality of care. In other instances, like
crowdsourcing decisions about the allocation of limited resources, the
17. See Caplan & Moch, supra note 1.
18. See Cha, supra note 1 (recounting that in the week following the announcement, Chimerix
stock was up 29 percent).
19. Infra Part II.
20. Infra Part III
21. Infra Part III.A.
22. Infra Part III.B.
23. Infra Part III.C.
24. Infra Part III.D.
25. Infra Part IV.

MONTANIO PROOF- TO PUBLISHER FINAL.docx	
  

2016]

MEDICINE 2.0: HAVE WE GONE TOO FAR?

11/4/16	
  	
  5:04	
  AM	
  

153

medical community needs to work together to reject some iterations of new
technology that cannot be used in an ethical manner.
II. THE MODALITIES OF MEDICINE 2.0
To understand Josh Hardy’s story and probe its ethical complexities, it
is important to understand the technological landscape against which it
unfolded. The Internet has existed for decades, but many commentators
characterize its current iteration as Web 2.0. Web 2.0 is described as “the
new uses of the Internet as a social networking tool as well as a way to
create value through mass access and participation.”26 A 2008 study
revealed that 53 percent of people surveyed used at least two social media
accounts, while another 37 percent used at least one.27 This can include
giant social media platforms like Facebook and Twitter as well as blogs,
photo sharing accounts, and many others. A 2013 study by the Pew
Research Center determined that 72 percent of American Internet users
found general health information online, and that number is expected to
continue to grow.28
Social media sites have enabled people to harness the power of their
networks in a process known as crowdsourcing. Crowdsourcing can take a
variety of different shapes but broadly occurs when someone tries to
“utilize the power of a distributed group of people to achieve a given
result.”29 Companies can utilize this process on a large scale.30 For
example, General Mills has created a variety of ways for customers to
provide feedback on its new products, marketing, ingredients, and customer
service.31 Crowdsourcing can also happen on a micro level when friends
consult with one another on topics ranging from which restaurant in town is
26. Terra Stump et al., The Emergence and Potential Impact of Medicine 2.0 in the
Healthcare Industry, 90 HOSPITAL TOPICS 33 (2012) (recalling how Web 1.0 was designed for
information gathering, not interacting with the material).
27. Id. at 35.
28. Susannah Fox & Maeve Duggan, Health Online 2013, PEW RES. CENTER’S INTERNET &
AM. LIFE PROJECT (Jan. 15, 2013), http://www.pewinternet.org/2013/01/15/health-online-2013/
(sharing that people searched everything from serious medical conditions to minor health
ailments).
29. See Jonathan J. Darrow, Crowdsourcing Clinical Trials, 98 MINN. L. REV. 805, 824–25
(2014) (describing the ways in which large organizations, such as businesses and governments,
have utilized different crowdsourcing techniques).
30. See id. at 824 (recalling situations in which prizes have been offered to whoever can find
the best solution to a problem or asking for more feedback from any number of parties in the
“nebulous” crowd).
31. Jartese, 5 Examples of Companies Innovating With Crowdsourcing, INNOCENTIVE (Oct.
18, 2013), http://www.innocentive.com/blog/2013/10/18/5-examples-of-companies-innovatingwith-crowdsourcing/ (recounting the General Mills World Innovation Network (G-WIN) where
anyone can submit a new idea to the company via the website).
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the best to who knows someone with influence at a pharmaceutical
company.32 Social media makes it possible for a user to request feedback
on a given topic, parse through the responses, and decide which answers are
most helpful, relevant or credible.
Another popular site that runs on crowdsourcing is Change.org.33 On
this website, anyone can start a petition to advocate for a cause they care
about and encourage people they know to virtually sign the document.34
These petitions often get circulated via other social media platforms and
have been used to affect change at a variety of organizations, including
large companies, government agencies, and small businesses.35 Several
such petitions were started on the behalf of Josh, and the largest of these
had nearly 20,000 supporters in less than a week.36
Web 2.0 led to Medicine 2.0 and Health 2.037: interchangeable terms
coined in 2008 that refer to “web-based services for healthcare consumers,
caregivers, patients, health professionals, and biomedical researchers which
use the Web 2.0 technologies to enable things such as participation and
collaboration among user groups as related to healthcare.”38 Proponents of
Health 2.0 claim that social networking can improve the quality of care by
increasing interactions between doctors and patients, while simultaneously
reducing health care costs.39 At its core, Health 2.0 is about active patient
participation, which correlates with people discussing and sharing ideas on
social media.40
Health 2.0 differs from the traditional vision of medicine, which was
more paternalistic. In the classic model, people with formal medical
training and degrees, including doctors and nurses, were generally the only
32. See Krissy Brady, 11 Incredible Ways to Crowdsource Your Life, ECOSALON (Dec. 22,
2014), http://ecosalon.com/11-incredible-ways-to-crowdsource-your-life/ (listing ways that
individuals can utilize crowdsourcing to decrease their commute, find potential dates, decide
where to eat, and even diagnosis a personal medical problem).
33. About, CHANGE.ORG, https://www.change.org/about (last visited Sept. 16, 2015).
34. Id.
35. See Change.org Year in Review: What You Changed in 2014, CHANGE.ORG (Jan. 13.
2015), https://www.change.org/year-in-review/2014 (stating that over 5,000 petitions were
considered victories, thus achieving the site’s intended effect).
36. Regina Breedlove, Release Brincidofovir for Compassionate Use to Treat the Adenovirus
Plaguing 7-Year Old Josh Hardy Right Now, CHANGE.ORG, https://www.change.org/p/chimerixrelease-brincidofovir-for-compassionate-use-to-treat-the-adenovirus-plaguing-7-year-old-joshhardy-right-now (last visited Sept. 25, 2015).
37. Marjolijn L. Antheunis et al., Patients’ and Health Professionals’ Use of Social Media in
Health Care: Motives, Barriers and Expectations, 92 PATIENT EDUC. & COUNSELING 426, 427
(2013) (utilizing the terms Medicine 2.0, Health 2.0, and eHealth interchangeably).
38. Stump, supra note 26, at 33.
39. See id.
40. See id. at 34 (observing that social networking has evolved beyond email and chat rooms
to “sophisticated virtual networks”).
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available sources of medical information.41 Health 2.0, by contrast,
frequently removes the formally trained health care provider from the
equation and allows people to gain medical knowledge through direct peerto-peer connections.42 With the Internet, not only can people look up almost
any medical study, they can also write reviews about their healthcare
providers, consult with patients across the globe about their experience with
similar symptoms, and read about breakthrough biopharmaceutical and
biomedical devices that are improving the quality of life for patients.43 For
example, a recent survey suggests that 35% of adults living in the United
States have used the Internet to figure out if they or someone they knew had
a specific medical condition.44 Of those people, just under half then went to
a medical provider, armed with medical information from the Internet, and
had their diagnosis confirmed.45 This trend will likely continue to increase
in the future.46
Some of the social media platforms used in Health 2.0, such as
Facebook or Twitter, are familiar to almost anyone with Internet access.47
These were the first tools used by Josh Hardy’s family to raise awareness
about his dire circumstances. Healthcare companies, such as hospitals, have
made a greater effort in recent years to engage with their current and
potential patients using social media.48 As of 2011, approximately one in
six hospitals in the United States used some sort of social media, most

41. See Sue Hollander & Don Lanier, The Physician-Patient Relationship in an Electronic
Environment: A Regional Snapshot, 89 BULLETIN MED. LIBRARY ASS’N 397 (2001) (describing
how the internet has made medical information available to patients that was previously only
accessible by physicians).
42. See Stump, supra note 26, at 34–35 (noting that many people learned information about
healthcare from the Internet, but only half of those people ever shared that information with their
medical provider).
43. See Antheunis, supra note 37, at 428 (reporting that the main reasons patients turn to
social media for health-related purposes are to increase their knowledge about a health issue,
exchange advice, and seek social support). See also Stump, supra note 26, at 35–36 (describing
the various platforms available for patients and the proliferation of websites tailored to health care
practitioners).
44. See Fox & Duggan, supra note 28, at 2 (noting that certain groups are more likely to use
the Internet this way, including women, young people, white adults, those with advanced degrees,
and those living in households earning at least $75,000 annually).
45. See id. (recounting that 41 percent of people had a medical provider confirm their
diagnosis while another 2 percent said the doctor partially confirmed the diagnosis).
46. See Antheunis, supra note 37, at 430 (recounting how several studies have predicted that
the Internet will increasingly impact the healthcare sector).
47. See id. at 428 (noting that Twitter and Facebook were the most popular social media
platforms for patients to use in a healthcare context, while YouTube and LinkedIn were used far
less frequently).
48. See Stump, supra note 26, at 35 (reporting that 965 hospitals used social networking as a
communication tool in 2011).
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commonly Facebook and Twitter, but also YouTube channels and blogs. 49
There are even conferences, such as the annual Social Media in the
Pharmaceutical Industry conference held in London, dedicated to how the
pharmaceutical industry can better use social media to market their products
and engage with customers to promote their business.50 Other social media
platforms are designed entirely for a healthcare purpose.51 Some social
media platforms are geared towards the healthcare industry.52 For example,
Sermo and Doc2Doc are modeled after traditional social media programs
but designed specifically for physicians to network with each other,
including exchanging information about novel cases or crowdsourcing
advice on a challenging patient.53 Still other platforms are for patients to
connect with people with similar conditions, such as PatientsLikeMe, which
claims to “make healthcare better for everyone through sharing, support,
and research.”54 Medicine 2.0 can take a variety of forms and the following
sections will describe a few of them in greater detail.
A. Crowdsourcing and Compassionate Use
Josh Hardy’s story involves the intersection of crowdsourcing and
social media in the context of compassionate use. The introduction to this
paper demonstrated how Hardy’s family used crowdsourcing to facilitate
access to a particular drug and this section will explain the traditional
infrastructure of compassionate use. Pharmaceutical companies develop
drugs, and the FDA, via the Center for Drug Evaluation and Research,
ensures that new drugs are safe and effective before approving them for sale
to the public.55 The approval process requires the company to submit an

49. Id. (noting that 777 hospitals used Facebook, 486 had a YouTube channel, 714 had a
Twitter handle, and 120 maintained some kind of blog).
50. See Social Media in the Pharmaceutical Industry, SMI GROUP, https://www.smionline.co.uk/pharmaceuticals/uk/social-media-in-the-pharmaceutical-industry (last visited Sept.
18, 2015).
51. See Stump, supra note 26, at 35 (illustrating how the website PatientsLikeMe.com allows
for social networking with a specific health care focus).
52. See Antheunis, supra note 37, at 430 (revealing how their study data showed that patients
and providers use social media for different reasons and gravitate towards different platforms)..
53. Matthew O’Donnell, Top 5 Social Media Sites for Physicians, HEALTHECAREERS.COM
(Feb.
10,
2012),
http://www.healthecareers.com/article/top-5-social-media-sites-forphysicians/168490.
54. About Us, PATIENTSLIKEME, https://www.patientslikeme.com/about (last visited
September 23, 2015).
55. The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective, U.S. FOOD &
DRUG
ADMIN.
(Nov.
6,
2014),
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143534.htm. See also CDER: The
Consumer Watchdog for Safe and Effective Drugs, U.S. FOOD & DRUG ADMIN. (Aug. 12, 2011),
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143462.htm (describing how the
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Investigational New Drug Application, which the FDA and an Institutional
Review Board must review and approve before clinical trials with human
subjects can begin.56 Before the FDA approves the drug, the product will go
through three phases of clinical study.57 The first phase involves studying
how the product impacts healthy patients.58 If no unacceptable dangers are
found, the product proceeds to phase two, in which the effectiveness of the
drug is tested on patients who actually have the targeted illness.59 The third
phase is an expanded trial with more subjects, ranging from hundreds to
several thousand before a final New Drug Application is submitted.60 Thus,
typically, if a patient wants to receive a specific drug that has yet be
approved, the only way to do so would be by being selected for a clinical
trial.
The compassionate use program was developed in response to a
demand from patients who were dealing with terminal or serious illnesses
and, often lacking any alternative, wanted access to a particular drug still in
a trial phase.61 Many of these patients were not eligible for ongoing clinical
trials for various reasons. For example, a drug may be tested in a clinical
trial for one particular type of cancer, and a patient, in conjunction with his
physician, may feel that the drug may help treat a different type of cancer
not currently being tested.62 In other instances, a patient may be excluded
from a clinical trial because he or she has a variety of medical conditions,
and the study needs to isolate the effect of the study drug on a particular
illness.63
If the patient decides to seek a compassionate use exemption, his or
her doctor fills out paperwork that is submitted to the FDA for approval.64
In recent years, the FDA has received an increasing number of requests,
center’s evaluation process “prevents quackery, but also provides doctors and patients the
information they need to use medications wisely”).
56. See The FDA’s Drug Review Process: Ensuring Drugs Are Safe and Effective, supra note
55.
57. Id.
58. Id.
59. Id.
60. Id.
61. See Jonathan J. Darrow et al., Practical, Legal, and Ethical Issues in Expanded Access to
Investigational Drugs, 372 N. ENG. J. MED. 279 (2015) (describing the history of the program that
arose out of the AIDS epidemic).
62. See Gaffney, supra note 5.
63. See Martin Fortin et al., Randomized Controlled Trials: Do They Have External Validity
for Patients with Multiple Comorbidities? 4 ANNALS FAMILY MED. 104 (2006) (noting that many
randomized controlled trials exclude patients with multiple comorbid conditions to increase the
internal validity of their findings).
64. See Gaffney, supra note 5 (outlining steps taken by the FDA to increase access to the
compassionate use program, including a drastic reduction in the amount of paperwork doctors are
required to submit).
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from 1,000 in 2010 to 1,200 in 2011.65 The FDA has approved 98% of the
individual applications submitted to the agency as of late May 2014.66 After
the FDA approves the expanded access, the company providing the drug
can decide if it wants to participate.67 More broadly, there are four types of
expanded access, ranging from single patient to a large patient population,
and the company providing the drug chooses which type it is willing to
pursue.68 A company can either create a new clinical trial for a
compassionate use patient or amend an ongoing trial to accommodate the
new patient.69 Recent FDA guidance allows companies, in some
circumstances, to charge a “reasonable” amount to the patient (or their
insurance, though most insurances will not pay for experimental treatment)
to cover only the direct cost of manufacturing, shipping, and monitoring of
the drug.70
The FDA has no legal authority to compel a company to provide a
drug even after compassionate use status is granted.71 The court system has,
thus far, decided that patients do not have a constitutional right to
experimental treatment.72 Unless this changes, the final decision to grant or
not grant a drug for compassionate use will rest with the pharmaceutical

65. See Brower, supra note 5 (quoting Richard Klein, director of the patient liaison program
at FDA’s Office of Special Health Issues).
66. Kroll, supra note 3.
67. See Gaffney, supra note 5 (noting that although the FDA frequently works with
manufacturers to facilitate increased access, the company ultimately has the sole discretion to
provide the drug).
68. See id. (describing the four types of expanded access which include: (1) Single Patient
(Emergency Access), for patients that do not have time to obtain written permission from FDA,
(2) Single Patient (Regular Access), which allows one patient to pursue compassionate use, (3)
Intermediate Size, which allows for multiple patients to pursue compassionate use, and (4)
Treatment, which would allow for widespread use).
69. See id.
70. See id. (qualifying this compensation scheme by saying that in order to charge, companies
must meet a four part test: (1) the drug must exhibit evidence of a clinical benefit; (2) data from
the trial is essential to obtaining future approval for it; (3) The trial could no be conducted without
charging; (4) The amount being charged is reasonable). See also Expanded Access: Information
for
Patients,
U.S.
FOOD
&
DRUG
ADMIN.
(July
31,
2015),
http://www.fda.gov/ForPatients/Other/ExpandedAccess/ucm20041768.htm.
71. See Gaffney, supra note 5 (noting that this creates a system where more applicants are
approved for compassionate use than are actually receiving the drugs from the companies that
own them).
72. See Abigail Alliance for Better Access to Dev. Drugs v. von Eschenbach, 495 F.3d 695
(D.C. Cir. 2007) (holding that a college student diagnosed with head and neck cancer did not have
a constitutionally protected right to an experimental medication before the FDA had approved the
drug for sale). See also Andrea Beth Ott, At the Altar of Autonomy: The Dangerous Territory of
Abigail Alliance v. von Eschenbach, 56 BUFF. L. REV. 821, 822–23 (2008) (noting that if a
constitutional right had been found, there would be a profound impact on science and drug
development).
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company, resulting in an unpredictable and unfair system of resource
allocation.
The story of #SaveJosh that appeared in the media made it difficult to
understand why anyone with the power to potentially save a life would
withhold a drug from a dying child. The media fueled an image of Chimerix
as another giant, unimaginably wealthy pharmaceutical company, like other
drug companies that people might be more familiar with, such as Merck or
Pfizer.73 However, Chimerix is a small biopharmaceutical start-up; about
fifty-five people worked there at the time that Josh Hardy’s family made
their plea.74 Brincidofovir, the drug Josh received, which is still in clinical
testing phases today, is not only Chimerix’s primary product, but their only
product.75
Drug development and the accompanying clinical trials are expensive.
Some companies may be in a position to provide a drug for free to patients
accepted through compassionate use, while others may not.76 Since
companies are only allowed to charge for the cost of manufacturing the
drug, many companies may have to bear the costs associated with
monitoring the patient after the study concludes, particularly if, as in Josh
Hardy’s case, the patient is put in a new clinical trial.77 In addition, the
majority of insurance plans do not cover experimental treatment and clinical
trials.78 In denying the initial requests to provide this drug to Josh,
Chimerix, which had engaged in compassionate use programs in the past,
stated that they had decided to stop granting that type of access so they
could focus their limited financial resources on the clinical trials needed to
get the drug approved and on the market.79
73. See Company Denies Drug to 7-Year-Old Boy Struggling Against Curable Virus, FOX
NEWS (Mar. 10, 2014, 9:34 AM), http://insider.foxnews.com/2014/03/10/drug-maker-chimerixrefuses-release-drug-7-year-old-josh-hardy-struggles-against-curable (reporting that Chimerix had
received $72 million dollars in federal funds, though neglecting to report other information,
financial or otherwise, that would have demonstrated to readers that Chimerix was a small
company). See also Kroll, supra note 3 (reporting how the issue was framed for the public as
“battling an evil pharmaceutical company concerned only about profits”).
74. Kroll, supra note 3.
75. See Investor Relations, CHIMERIX, http://ir.chimerix.com/ (last visited Feb. 15, 2016)
(stating that Brincidofovir is still in phase 3 of clinical trials).
76. See Gaffney, supra note 5 (noting that small start-up pharmaceutical companies, like
Chimerix, may be particularly concerned with the cost of administering a compassionate use
program since they do not have incoming revenue until their product is available for sale).
77. Id. (stating that FDA allows companies to charge for compassionate use treatments if they
meet the following four criteria: the drug must exhibit evidence of a clinical benefit, data from the
trial is essential for future approval, the trial could not be conducted without charging, and the
amount being charged is reasonable).
78. See Expanded Access: Information for Patients, supra note 70.
79. See Caplan, supra note 1 (describing how in 2011, Chimerix had received funding from
the Health and Human Service’s Biomedical Advanced Research and Development Authority and
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Of course, as for-profit enterprises, pharmaceutical companies have
other economic considerations. There seems to be general industry concern
that granting many compassionate use requests, even if done at cost, would
hurt future negotiations with insurance providers regarding the cost of the
drug when released to the public.80 CEOs and other pharmaceutical
executives are held responsible for profit margins by the shareholders,
boards, and other entities they work for.81 Even from a more practical
standpoint, drug companies have to make money on their products because
it is incredibly expensive to develop a drug from concept to market.82 A
recent study estimated that the average out-of-pocket cost for a drug that
successfully makes it to market is 1.4 billion dollars and rising.83 That does
not even take into account the fact that nearly nine out of ten drugs that start
the development process never make it to market, often because they
simply do not work or clinical testing uncovers unacceptable safety
hazards.84 Additionally, drug development takes years.85 Even if a
company is not just focused on their bottom line, but truly believes in a
mission of improving healthcare for people, it is easy to see under these
terms why companies might be hesitant to divert time and financial
resources to compassionate use programs that could be put towards getting
the product out to a broader market.
There are also the safety concerns related to dispensing a drug at the
test phase. Some candidates, particularly those facing eminent death from a
used that money to provide 215 patients with Brincidofovir for a small pox study; after funding
ended in 2012, Chimerix terminated its compassionate use program).
80. See Gaffney, supra note 5 (recalling how an FDA official stated that companies feared the
“reasonable” price requirement of compassionate use would prevent them from negotiating
significantly higher prices with insurance providers once the drug was approved for market).
81. See Cha, supra note 1 (noting that as a publicly traded company, Chimerix was
particularly vulnerable because their stock fluctuated with the news). See also Corporations 101:
The Role of Corporations and Corporate Governance in Maintaining U.S. Competitiveness,
BUSINESS
ROUNDTABLE
(July
2008),
http://businessroundtable.org/sites/default/files/
Corporations_101_The_Role_of_Corporations_and_Corporate_Governance.pdf (illustrating the
intertwined fiduciary relationship between a company’s management, including the CEO, the
Board of Directors, and shareholders).
82. See Rick Mullin, Cost to Develop New Pharmaceutical Drug Now Exceeds $2.5B,
SCIENTIFIC AMERICAN (Nov. 24, 2014), http://www.scientificamerican.com/article/cost-todevelop-new-pharmaceutical-drug-now-exceeds-2-5b/ (calculating the average out-of-pocket cost
to develop a new drug at $1.4 billion dollars and then adding additional costs to represent the
returns that investors lose out on during the extensive approval process).
83. See id. (estimating the cost at over two billion dollars because they also accounted for the
“$1.2 billion in returns that investors forego on that money during the 10-plus years a drug
candidate spends in development”).
84. Michael Hay et al., Clinical Development Success Rates for Investigational Drugs, 32
NATURE BIOTECH. 40, 40–51, (2014).
85. Biopharmaceutical Research & Development: The Process Behind New Medicines,
PHRMA (May 2015), http://www.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf
(stating that from the earliest stages to market, drug development can take up to ten years).
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terminal illness, are willing to risk negative side effects or serious adverse
reactions, including the possibility of death, from taking a still unproven
drug.86 While patients may be willing to take the risk, the company is in the
position of applying to the FDA for approval of their product, which
requires demonstrating that their drug is both effective and safe.87
Participants in clinical trials are carefully selected and many potential
participants are often excluded due to coexisting conditions that could cause
the drug to react differently.88 Companies can also exert a lot of control
over how their clinical trials are designed and run; however, when a drug is
approved for compassionate use, the company loses some of that control
and can be penalized by the FDA if the patient experiences adverse effects,
even if that patient was already dying.89 This concern was recently
substantiated when the FDA ordered a drug company to stop enrolling
patients in a clinical trial because of an adverse reaction experienced by
someone receiving the drug through a compassionate use situation. 90
Ken Moch was the CEO of Chimerix during the Hardy social media
campaign.91 Very few news outlets reported that in addition to receiving
hundreds of letters advocating for Josh, Moch and his employees received
death threats.92 Further, supporters of the campaign posted the personal
contact information of Moch and the entire Chimerix Board of Directors
online.93 Moch required a security guard to get to and from work.94
Officers were placed at the entrances to the office building so that
employees could feel safe being at the company, despite the threats.95 After
the Hardy family received Brincidofovir through the clinical trial, they
86. See Brower, supra note 5, at 1 (discussing how the FDA has to balance their job of
protecting the safety of patients with the desire of those same patients to take any means necessary
to save their lives).
87. See How Drugs are Developed and Approved, U.S. FOOD & DRUG ADMIN. (Aug. 18,
2015),
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/.
88. See Alexander Gaffney, Legislation Seeks to Overhaul FDA’s Compassionate Use
Program, REG. AFFAIRS PROF. SOC’Y (Dec. 2014), http://www.raps.org/RegulatoryFocus/News/2014/12/09/20946/Legislation-Seeks-to-Overhaul-FDAs-Compassionate-UseProgram/.
89. See id. (noting that the FDA can put a trial on a “partial clinical hold,” meaning that
companies can no longer enroll new patients, or a “clinical hold,” which halts all on-going trials
completely).
90. See id. (describing how CytRx Corporation had a clinical trial placed on partial clinical
hold by the FDA after a patient with advanced-stage cancer who was not eligible for any existing
clinical trials died after receiving one of their products through compassionate use).
91. See Caplan & Moch, supra note 1.
92. Kroll, supra note 3.
93. See Caplan & Moch, supra note 1.
94. Id.
95. David Kroll, Chimerix CEO Out in Wake of Josh Hardy Compassionate Use Media
Frenzy, FORBES (Apr. 10, 2014, 9:33 AM), http://onforb.es/Q9ceFB.
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praised Moch for his efforts and collaboration with the FDA.96 Yet a month
later, Moch was fired from Chimerix.97 Since then, Moch has spoken at
conferences and co-authored articles about the issues with compassionate
use that often go ignored by the media.98
Chimerix had stated that they had stopped allowing compassionate use
in 2012 to focus on getting the drug to market, two years prior to receiving
the request from Josh Hardy.99 Moch later shared that Chimerix also lost a
major stream of funding at that time, which had supported the company’s
earlier forays into compassionate use.100 Moch, a father himself, was not
unsympathetic to the struggles of Josh and his family.101 However, Josh
was not the only candidate for compassionate use— in fact, hundreds of
patients requested the same expanded access.102 After funding was
unavailable, Moch constantly found himself in the difficult position of
having to deny requests, knowing that each denial could lead to someone’s
death.103 But if the company were to grant every request, or even some of
the requests, it would be difficult to allocate the financial or personnel
resources available to proceed with the actual clinical trial.104 Moch stated
he was thinking about the “many Joshes,” which represented everyone who
could be helped if the drug was brought to market as fast as possible.105
It seems unlikely that the people who simply clicked a button to sign
an electronic petition were thinking about the “many Joshes” when they
96. See Aimee Hardy, Chimerix Released the Medicine for Josh!, CARINGBRIDGE (Mar. 13,
2014),
https://www.caringbridge.org/visit/joshuahardy/journal/view/id/5321be78f0ac1f0417d130e7
(updating followers of the #SaveJosh Movement after Josh received Brincidofovir and thanking
the Chimerix and FDA for finding a way to help him).
97. Id.
98. See Caplan & Moch, supra note 1, the most widely circulated article that Moch coauthored.
99. See id. (noting that after BARDA funding ended, the company decided to discontinue
granting compassionate use requests. It is unclear if the policy was communicated publicly at that
time, but all compassionate use requests were denied from that point forward).
100. Id.
101. Kroll, supra note 95.
102. See Caplan & Moch, supra note 1. See also Kroll supra note 3 (recounting how Chimerix
had provided the drug to 430 patients before funding was canceled and Chimerix stopped granting
compassionate use requests).
103. See Cha, supra note 1 (noting that after Chimerix stopped granting compassionate use
requests, the company received 200 requests that were all rejected, including eighty people who
had adenovirus infections like Josh).
104. See Cohen, supra note 8 (reporting that Chimerix would have to spend $50,000 per
compassionate use patient in addition to diverting staff to handle the paperwork and other
technical aspects required by the FDA for the compassionate use program).
105. See Kroll, supra note 95 (“If you make an experimental medicine available to a particular
child, how do you not make it available to other children in that developmental process? This was
not just about Josh Hardy; it was about the many ‘Joshes.’ ”).
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implored Chimerix to provide the drug.106 With lopsided media coverage,
many did not consider the variety of financial and ethical factors that a
company would have to evaluate with each request.107 Turning down a
request from a person with a name, family, and smiling photographs—
knowing they will more than likely die—is a brutally difficult ethical
dilemma, particularly when the benefit to other potential, unknown patients
seems distant.108 Yet that is exactly the kind of choice Ken Moch faced,
and was fired for, at Chimerix. Crowdsourcing is not designed to consider
the complexities of compassionate use because it works by making an
emotional appeal rather than a balanced consideration of the issues. Yet this
ill-suited technology was what ultimately forced the decision to provide the
drug to Hardy.109
B. Direct-to-Consumer Research Products
Apple, the highest valued company in American history, recently
started releasing health-related products, demonstrating that large
companies are willing to invest in DTC medical products.110 In September
of 2014, Apple released a new mobile software application (“app”) called
Health on the iOS 8 mobile operating system.111 Health is an app that
aggregates personal biometric data from other healthcare and fitness apps in
one easily accessible place.112 This data might include, for example,
information about one’s medications, caloric output during a workout, or
blood sugar levels.113 In 2015, Apple introduced a product called
ResearchKit, which is an open source software framework that enables
developers and researchers to create apps for medical research, allowing
third parties to build on the Health concept.114 Apple users are able to
download these apps, enroll in research studies, and grant researchers

106. Kroll, supra note 3.
107. See id. (describing the media’s desire to sensationalize a story like a shark attack, stating
that they “smell and taste blood in the water and swarm for the kill”).
108. See id. (noting our desire to save a particular child when there is additional, sympathetic
identifying information included). See also Caplan, supra note 1 (describing a societal bias to save
children over elderly people and to help “identified persons over statistical lives”).
109. Caplan, supra note 1.
110. Verne Kopytoff, Apple: The First $700 Billion Company, FORTUNE, Feb. 10, 2015. See
also Dan Diamond, Apple’s HealthKit is Finally Here— After Bugs, Botches, and Boatloads of
Apple Hype, FORBES, Sept. 26, 2014 (showing that within the last year and a half Apple has
started releasing highly anticipated healthcare related products).
111. Health, APPLE, https://www.apple.com/ios/whats-new/health/ (last visited Apr. 1, 2016).
See also Diamond, supra note 96.
112. Id.
113. Id.
114. Research Kit, APPLE, https://www.apple.com/researchkit/ (last visited Apr. 20, 2015).
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access to personal data collected through surveys and iPhone sensors.115 On
their website, Apple claims that ResearchKit allows “everybody” to “do
their part to advance medical research . . . potentially transforming medicine
forever.”116 This perfectly summarizes the attitude surrounding Medicine
2.0. While people have touted the benefits of creating this kind of access for
patients, from Apple’s viewpoint, this is what patients and researchers are
morally obligated to do.117
Apple is arguably the most well-known company in the DTC market,
but there are other companies with products that go beyond mere data
entry.118 Personal genetic testing (“PGT”), allows consumers to purchase
test kits, collect DNA samples at home, and send the samples back to the
company for genetic sequencing.119 There are several companies that offer
this service for different purposes.120 Theoretically, these products could be
marketed to appeal to people seeking genealogical information about their
family or to predict the presence of diseases or traits with genetic
components.121 The services also vary because some offer complete
genome-wide scans while others are looking for specific genetic markers
associated with specific conditions.122
In addition to providing information to the individual consumer, many
of these companies also store and use the genetic information that
consumers provide for research.123 Just as there is significant variation in
the services offered, the focus and execution of research activities vary.
Knome offers complete genomic sequencing but also has an arm of their
company that is entirely focused on selling that information to external
research companies.124 Other companies, such as deCODE Genetics,
contact users and ask them to participate in internal research the company is

115. Id.
116. Id.
117. Id.
118. Valerie Gutmann Koch, PGTandMe: Social Networking-Based Genetic Testing and the
Evolving Research Model, 22 HEALTH MATRIX 33, 34–35 (2012).
119. Id. at 35.
120. See List of Personal Genomics Companies, INT’L SOC’Y OF GENETIC GENEALOGY,
http://isogg.org/wiki/List_of_personal_genomics_companies (last accessed on Apr. 28, 2016)
(compiling a list of companies that sell PGT products that provide information on health
conditions, genetic traits, or pharmacogenetics).
121. See Koch, supra note 118, at 36 (noting that deCODE Genetics offers genealogical
services and others such as Navigenics, Pathway Genomics, and Interleukin Genetics focus on
detecting specific traits. Some companies, such as 23andMe, offer both.).
122. See id. (describing a product called Knome that does a full genome scan).
123. Id.
124. Id. at 37 (describing KnomeDiscovery, a service that helps external researchers design
and execute research projects centered on genetic data).
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conducting on specific diseases.125 There is also a social media aspect to
some of the services, where users can choose to share the results of their
testing with other people on sites created by the companies and form
communities based on their genetic make-up.126
PGT companies describe their investigative actions as the
“democratization of research,” which foreshadows the next section’s
discussion of apomediation and is reminiscent of the discussion of
crowdsourcing in the previous section.127 These sites allow users to join
together to advocate for certain diseases to be studied over others, allowing
the companies to crowdsource their research agendas by surveying the
potential pool of research participants.128 Users can also share their genetic
information, and often do so without the oversight of the traditional medical
infrastructure of doctors and clinical researchers.
Several sites have already reported success with early PGT-based
studies, suggesting the potential to advance medical research and direct the
course of the medical field overall.129 In 2010, 23andMe researchers
published the first report using genome-wide association studies (“GWAS”)
in the reputable publication Genetics.130 GWAS use genetic information
collected through the company’s test kits coupled with the users’ self-report
of the presence of observable traits.131
One issue that PGT companies can meaningfully address is the
perpetual difficulty of finding participants to enroll in research studies. By
allowing users to select the area of study that they would like to see
investigated, researchers are more likely to have subjects who are eager to
participate, eliminating delays in research that frequently occur because of
under-enrollment.132 Alternatively, if PGT companies collect and sell data,
they have a large database of genetic information that can immediately be
mined for particular research projects, eliminating the need to find new

125. See id. at 38 (reporting that deCODE Genetics has already been able to conduct studies
that involve more than 10,000 people with the same disease through its website).
126. See id. at 40 (highlighting 23andME which has a password protected website allowing
users to participate in groups with people that share similar genetic traits, for the purpose of either
fostering new genealogical connections or providing support for people who are at a higher risk of
particular negative health outcomes).
127. Koch, supra note 118, at 35.
128. See id. at 42 (describing how 23andMe markets a product called Research Revolution,
where everyone who buys a testing kit gets to vote on which common diseases the company
should study).
129. Id. at 43.
130. Id.
131. Id. at 43–44 (noting that publication of the article was delayed as the editors considered
the new ethical issues this type of research presents).
132. Id. at 35.
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subjects for each new study.133 This may also facilitate the replication of
study findings, as the data set could be made available to multiple
researchers. Services that send kits to patients’ homes may also expand the
potential data pool and increase the diversity of study participants.134 PGT
companies may also benefit from long-term cost-savings in two ways. First,
the participants are already paying the company for the kit used to generate
information for potential research use, thus negating the expense typically
shouldered by researchers to pay for participant recruitment.135 Second,
money would be saved by reducing the time and cost associated with
recruiting participants.136
C. Apomediation
Another variation of social media technology intersecting with
medicine is the concept of apomediation.137 Earlier iterations of medicine
were about hierarchal relationships between providers and patients, with the
traditional medical establishment controlling and dispensing information to
a passive recipient.138 These vertical relationships might take the form of
doctors conveying information to patients who do not have the knowledge
base to challenge or participate in the process, or researchers designing
trials where the subjects participate without input into the overall design.139
Apomediation is when the middleman, often the FDA or a doctor, is either
removed completely from the health care decision-making process, or given
a diminished role.140 In contrast to traditional medicine, “apomediation is
133. Koch, supra note 118.
134. Id. at 35. See also Press Release, Apple Introduces ResearchKit, Giving Medical
Researchers the Tools to Revolutionize Medical Studies, APPLE (Mar. 9, 2015),
http://www.apple.com/pr/library/2015/03/09Apple-Introduces-ResearchKit-Giving-MedicalResearchers-the-Tools-to-Revolutionize-Medical-Studies.html (noting that the participant pool
can be greatly expanded by allowing people to contribute data collected on their phone rather than
requiring people to travel to a research institution).
135. But see Koch, supra not 118, at 41 (noting that to encourage users to provide information
for specific studies already in progress, 23andMe provided all of their services for free). See also
id. at 43 (noting that 23andMe’s Research Revolution line was ultimately discontinued because it
failed to make a profit but that the company’s research efforts continue by allowing people to
purchase the test kit and opt to allow their information to be used for research).
136. See Recruit, BIONEWS SERVICES, http://bionewsservices.com/2015/02/13/recruit/ (last
accessed on Apr. 28, 2016) (acknowledging that 32 percent of total clinical trial costs are incurred
during participant recruitment and that on average, clinical trials run 25 percent over their deadline
because of recruitment issues).
137. Dan O’Connor, The Apomediated World: Regulating Research When Social Media Has
Changed Research, 41 J. LAW MED. & ETHICS 470, 471 (2013).
138. See id. at 471 (discussing how the hierarchical system created an unequal balance of
power between patients and providers).
139. Id. (defining the traditional doctor patient relationship as “intermediation,” noting that the
patient and doctor are on different levels in the hierarchical framework).
140. Id.
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envisioned as a more horizontal, peer-to-peer style of information exchange
in which no single apomediary is essential to the process.”141 Apomediation
is what social media platforms and crowdsourcing allow patients to do
together and has allowed patients to have more leverage in their
relationships with medical professionals and researchers, if they rely on
those relationships at all.142
In the medical context, apomediation primarily occurs in the research
sector, when patients have the opportunity to organize their own studies.143
This can range from collaborations between patient representatives and
researchers to almost completely patient-driven projects. For example,
when Emory University School of Medicine planned a trial studying
different epilepsy drugs, the patient representative, Brandy ParkerMcFadden, who has epilepsy, made some key suggestions that altered the
design of the study to better reflect patient needs.144 Patient representatives,
who work with traditional researchers to develop goals and protocols for
studies, are becoming an increasingly common part of research teams.145
This increase has been driven in large part by a non-profit called the
Patient-Centered Outcomes Research Institute (“PCORI”), which Congress
created as part of the Affordable Health Care Act.146 While the researchers
still bring medical and scientific expertise to the process, the patient
representative embodies the horizontal role central to the concept of
apomediation.147 PCORI funds a variety of medical research projects,
contingent upon keeping patients involved in the design of the projects.148
Susan Sheriden, Director of Patient Engagement at PCORI, stated that the
141. Id. at 471 (noting that the term apomediaries comes from the Latin word apo, meaning
“to stand by” or “next to”).
142. See id. at 472 (highlighting the direct relationship between the growth of online social
networking and crowdsourcing in healthcare).
143. This is true because patients can research medical conditions without the assistance of
doctor, but cannot completely remove the “middle-man” from the process because they still rely
on doctors to prescribe most medications. See Gary Stern, Self-Diagnosing: On the Proper Role of
Sites Like WebMD, THE ATLANTIC, Oct. 5, 2012 (describing how patients have used websites like
WebMD to better prepare for interactions with a physician).
144. See Amy Dockser Marcus, Design Power: Patients Play Researchers in Drug Trials, THE
WALL STREET JOURNAL, Sept. 29, 2014 (describing Parker-McFadden’s initial concerns that she
was not viewed as an equal on the committee designing the epilepsy study, but eventually played a
significant role in the development of the research).
145. See id. (acknowledging that some researchers are hesitant to include patients in the trial
design process, then providing several examples of studies that involved patients at this stage).
146. See id. (explaining that all trials that receive funds from PCORI must include patients in
the design process); See also About Us, THE PATIENT-CENTERED OUTCOMES RES. INSTIT. (Oct.
6, 2014), http://www.pcori.org/about-us.
147. See O’Connor, supra note 137 (defining apomediation as centered on peer-to-peer
horizontal relationships, or in this case patient-to-patient).
148. What We Do, THE PATIENT-CENTERED OUTCOMES RES. INSTIT. (Sept. 10, 2014),
http://www.pcori.org/content/what-we-do.
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purpose of fostering such participation is primarily to make sure that
medical research is grounded in reality by being relevant to the applicable
patient community.149 The drawback to this approach is that by having
more people critique and develop trial protocols, the process may take
longer.150 However, by creating PCORI, the U.S. government has made a
strong statement that this type of participation is favorable despite
potentially slowing down the research process.
The FDA has also gotten involved by collecting patient-reported
outcomes (“PRO”); instead of collecting information observed by
researchers, the agency gathers information directly from patients about
their experiences, symptoms, or characteristics.151 The PRO Task Force at
PCORI has defined a broader category of patient-generated data as “healthrelated data—including health history, symptoms, biometric data, treatment
history, lifestyle choices and other information—created, recorded, gathered
or inferred by or from patients or their designs (i.e., care partners or those
who assist them) to help address a health concern.”152 This definition
incorporates the idea that the type of data generated by patients may vary
widely, from concrete numbers to open-response type prose.153 This type of
research still requires professionals to determine how to incorporate this
information into their work and is further limited by the lack of consistency
and quality of this type of data.154 The whole purpose of emphasizing this
type of data collection is to have patients participate more in the research
process and to have their needs shape the course of research.
Finally, there have been recent incidents where medical research has
radically departed from traditional methodology to pursue a completely
apomediated approach. In 2011, Nature Biotechnology published a study
about the effects of using lithium on patients with ALS based on PRO
data.155 What makes this study particularly novel is that it was
conceptualized, run, and supported entirely by the ALS patients themselves;
professional researchers were only brought in during the final stage to

149. Marcus, supra note 144.
150. See Lynn Howie et al., Assessing the Value of Patient-Generated Data to Comparative
Effectiveness Research, 33 HEALTH AFFAIRS 1220 (2014) (reiterating that research, particularly
regarding treatments, can take over a decade to conduct).
151. See id. at 1221 (noting that often the data provided are not truly outcomes but rather
descriptions of experiences).
152. Id. at 1222.
153. Id.
154. See id. at 1225 (describing the subjectivity of patients that can be difficult to account for,
such as the variation of patients describing their pain on a scale of one to ten).
155. See Paul Wicks et al., Accelerated Clinical Discovery Using Self-Reported Patient Data
Collected Online and a Patient-Matching Algorithm, 29 NATURE BIOTECH. 411 (2011)
(describing the instrumentality of PatientsLikeMe to the study).
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analyze the results.156 One patient with ALS suggested on a website,
PatientsLikeMe, that other patients with ALS should track their experiences
taking lithium to treat their condition.157 Other users participated, added
their own suggestions, and recruited other people with ALS to participate as
well.158 This is true apomediation, in the sense that the people suggesting,
designing, and conducting the study were all also participants; thus, the
middle-man has been almost entirely removed. This was heralded by the
media as a new era of medical research, particularly because, like DTC
research products, this could address the lack of enrollment in studies.159 If
patients rely on each other to design the most relevant studies and
encourage each other to participate in them via their social networks, they
could advance research faster than traditional modalities.
III. THE ETHICAL ISSUES OF MEDICINE 2.0
Crowdsourcing compassionate use, DTC research products, and
apomediation all deliver potential new means for the advancement of
medicine by making medicine more accessible to the average patient,
speeding up cumbersome processes, and allowing patients to have a greater
stake in setting the field’s priorities. However, there are a multitude of
ethical issues that have yet to be sufficiently addressed. Despite society’s
unyielding demand for innovation, it is imperative that ethicists and other
stakeholders consider the drawbacks of these new modalities before fully
committing to regularly employing them.
A. Social Justice
The most glaring problem with crowdsourcing compassionate use is
that there are obvious social justice issues. Josh and his family were not the
first, and will not be the last, to use social media to gain this type of access.
Before them, other individuals like Nick Auden, Darlene Grant, Andrea
Sloan, and Jack Fowler’s family all used social media, with varying
success, to compel companies to provide their products for compassionate
use.160 Since Josh Hardy, others including Mikaela Knapp, have
156. See O’Connor, supra note 137, at 472 (detailing how the patients collected their
information in an online spreadsheet that was then shared with researchers).
157. See Wicks et al., supra note 155 (noting the medical community’s skepticism regarding
the antecdotal reports that drove the patients to create their own study).
158. See O’Connor supra note 137, at 472.
159. See id.
160. See Claire Martin, Nick Auden, Who Lobbied to Use Experimental Skin Cancer Drug, Has
Died,
THE
DENVER
POST
(Nov.
29,
2013),
http://www.denverpost.com/breakingnews/ci_24625182/nick-auden-who-lobbied-useexperimental-skin-cancer (reporting on the death of Auden, who did not receive a drug via
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followed.161 These are all cases that have garnered mainstream media
attention, and the individuals (or their families) have attempted to capitalize
on crowdsourcing to put pressure on pharmaceutical companies of various
sizes. Remember that hundreds of people request compassionate use
exemptions from the FDA each year, but only some garner significant
attention on social media.162 Looking at these cases in the aggregate, some
interesting trends appear.
The most apparent trait is that every person in these social media
campaigns appears to be white.163 There do not appear to be any statistics
available relating to the race of people who have requested compassionate
use through the FDA or actually received drugs in this method. From the
social media aspect, Facebook is also unable to provide concrete data on the
ethnic breakdown of their users because that is not information that is
included in a user’s online profile.164 However, data engineers at Facebook
have been able to provide estimates based on a statistical analysis of

compassionate use, despite getting half a million people to sign his Change.org petition); See also
Darlene Gant, Mom Dying of Cancer, Inspires Drug Maker to Release Trial Drug Pertuzumab
Via
YouTube
Video,
THE
HUFFINGTON
POST
(May
1,
2012),
http://www.huffingtonpost.com/2012/05/01/darlene-grant-mom-dying-cancer-videogenentech_n_1465938.html (recounting how a mother posted her plea for a drug via
compassionate use to the website YouTube); See also Darlene Grant, My Cancer Story, CANCER
AVENUE, http://www.canceravenues.com/darlenes-corner/my-cancer-story (recalling a patient’s
first person account of using social media to gain access to a drug via compassionate use). See
also Tracy Jan, Hopes of Family, Firm Collide on Unproven Drug, THE BOSTON GLOBE (Jan. 31,
2014), http://www.bostonglobe.com/news/nation/2014/01/31/family-quest-for-experimental-drugunderscores-dilemmas-for-patients-drug-companies/2BFtW16dPf6RHOSphehcgL/story.html
(explaining the ethical tensions that underscored a meeting between a family seeking
compassionate use and the pharmaceutical company that was not willing to provide the drug); See
also William Hudson, In Cancer Drug Battle, Both Sides Appeal to Ethics, CNN (Sept. 28, 2013)
(describing the case of Andrew Sloan who was using social media to try to compel a company to
provide a drug to help her survive ovarian cancer).
161. See David Kroll, Husband Seeks Compassionate Use of Anti-PD-1 Drug For Young Wife
With Rare Kidney Cancer, FORBES (Mar. 26, 2014) (acknowledging that the couple seeking the
drug contacted him specifically to gain exposure to their need because he had previously reported
on the Josh Hardy case).
162. See Kroll, supra note 3 (cautioning his readers to remember that “in hospitals around the
country- or at home for those without intensive care access- thousands of faceless and nameless
people suffer from similar infections sometimes without computers or Internet access, most
without the PR savvy to mount a similar campaign.” See also Gaffney, supra note 5 (stating that
in 2012 over 1,200 patients participated in the FDA’s compassionate use campaign. Less than a
dozen people have had large scale compassionate use campaigns on social media judging by
media coverage of the topic, supra note 140).
163. See Kroll, supra note 161 (reporting on various people who have lunched public
campaigns for compassionate use, all of whom appear to be white).
164. Mary Ellen Slayter, Facebook Finds a Way to Predict Your Ethnicity, SMARTBLOG (Aug.
2, 2010), http://smartblogs.com/social-media/2010/08/02/facebook-finds-a-way-to-predict-yourethnicity/.
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people’s names.165 Their report suggests that Caucasian and Asian/Pacific
Islanders originally dominated Facebook, though the site has become
increasingly diverse in recent years.166 The study also notes that Facebook
users are more likely to communicate and interact with people of their own
race.167 Thus, if Facebook users are sharing stories or circulating online
petitions, they may be more likely to see and engage with the story if the
user is someone of their own race.
Additionally, the mainstream media plays a significant part in which
stories go “viral” by reporting on them and thus increasing their popularity.
However the media also struggles with social justice issues.168 This has
been written about in other contexts, but not applied to the compassionate
use issue. For example, there has been discussion in academia about how
the race of a missing child impacts the amount of media coverage the story
receives.169 Critics have called this phenomenon “Missing White Girl
Syndrome,” observing that the media portrays missing white children as
innocent victims and missing children of color, if they even cover the story
at all, as culpable quasi-victims.170 There are many possible explanations
for why this disparity in coverage exists. Washington Post columnist
Eugene Robinson called the ideal character for this type of story a “damsel
in distress” and described the archetype this way:
A damsel must be white. This requirement is nonnegotiable. It
helps if her frame is of dimensions that breathless cable television
reporters can credibly describe as “petite,” and it also helps if
she’s the kind of woman who wouldn’t really mind being called
“petite,” a woman with a good deal of princess in her personality.
She must be attractive — also nonnegotiable. Her economic
status should be middle class or higher, but an exception can be

165. Id.
166. Id. (qualifying that the researchers only analyzed the social media activity of the four
largest ethnic groups in the U.S., Caucasians, African-Americans, Asian/Pacific Islanders, and
Hispanics).
167. Id.
168. See Lisa Wade, Racial Bias and How the Media Perpetuates It With Coverage of Violent
Crime, PACIFIC STANDARD (Apr. 17, 2015), http://www.psmag.com/books-and-culture/racialbias-and-how-the-media-perpetuates-it-with-coverage-of-violent-crime (noting that 51 percent of
people arrested for violent crimes occurring in NYC are black but that 75 percent of the media
reports that cover violent crime in the same area report on black perpetrators).
169. See Missing White Girl Syndrome, JOURNALISM CTR. ON CHILDREN & FAMILIES,
http://journalismcenter.org/when-a-child-dies/missing-white-girl.html (last visited Apr. 20, 2016)
(noting that 42 percent of missing children are black, but the media coverage is so inadequate that
there is a separate alert system for missing children of color).
170. Id.
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made in the case of wartime . . . Put all this together, and you get
24-7 coverage.171
Both commentators and journalists admit that there is a racial
hierarchy in the way that crimes and other news stories are reported.172 It is
often attributed to the fact that media viewers and the people creating the
news find people of the same race more relatable.173 Racial minorities are
underrepresented in journalism jobs; 32 percent of the population is nonwhite or Hispanic, while only 22 percent of television reporters and 13
percent of newspaper journalists identify as non-white or Hispanic.174
Collectively, this helps explain why popular social media stories about
compassionate use, propelled by the traditional media, portray exclusively
white people. Instead of being a case of “Missing White Girl Syndrome,”
compassionate use stories are subject to “Dying White Person Syndrome.”
While gender seems to be less of a factor in which stories gain traction
in the public consciousness, family status is critical. In almost every news
story about compassionate use, the person who needed the drug could be
sorted into one of two categories: either the child of a loving family or a
parent of a loving family.175 Though it has not been discussed in a
compassionate use context, these stories may be appealing because these
candidates seem more deserving of aid.176 The news stories emphasize this
angle, almost always including pictures of the patient surrounded by his or
her family.177 The patients themselves, at least the adult ones, use this angle
171. Eugene Robinson, Op-Ed., (White) Women We Love, WASH. POST, June 10, 2005,
http://www.washingtonpost.com/wp-dyn/content/article/2005/06/09/AR2005060901729.html
(responding to the intense media coverage of the disappearance of Natalie Holloway in Aruba).
172. See Tara McKelvey, Cleveland Abductions: Do White Victims Get More Attention?, BBC
NEWS (May 9, 2013), http://www.bbc.com/news/magazine-22441124 (noting that 80 percent of
the coverage of missing children is devoted to non-African American children).
173. Id.
174. Missing White Girl Syndrome, supra note 169 (quoting Maynard as saying that journalists
have a “tendency to consciously or unconsciously cover communities that remind them of their
own”).
175. See Kroll, supra note 161 (recounting various news stories that often lead with the family
angle of the story).
176. See Govind Persad et al., Principles for Allocation of Scarce Medical Interventions, 373
THE LANCET 423, 425–26 (detailing the variety of ethical considerations that could be used to
allocate finite medical resources like vaccines or organs). The article says one method could be
allocating based on “social value,” which prioritizes “specific individuals to enable them to
promote other important values, or rewards them for having promoted these values.” The article
cautions that actually implementing a social values based method of allocation is not ethically
advisable because of the variety of legitimate views on what is socially valuable. However, the
article notes that at one point in time Seattle had a dialysis policy that, among other categories,
favored parents. While the article demonstrates that this is a policy that should be rejected, it
shows that this type of bias for parents and families is common. Id.
177. See e.g. Jan, supra note 160 (showing then-six-year-old Jack Fowler surrounded by his
family in the midst of his battle to gain compassionate use access).
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to attract sympathy in their outreach efforts on social media. Nick Auden
garnered 500,000 signatures on a Change.org petition for his compassionate
use request and started a website called “Save Locky’s Dad.”178 On the
website, seven-year-old Lachlan “Locky” Auden, the eldest of Nick’s three
children, was featured in a linked YouTube video explaining how much he
loved his father and asking people to support their social media campaign to
get a medication via compassionate use.179 Similarly, many media stories
about Darlene Gant, a woman dying of breast cancer, conspicuously
included the fact that she was also a mother either in the headline or in the
first paragraph of the report.180
Out of all the adults mentioned above, only Mikaela Knapp was not a
mother or a child; nonetheless, the media coverage in her case emphasized
her potential to be a mother.181 The headline about her in Forbes
highlighted that her husband led the compassionate use campaign for his
“young wife.”182 By emphasizing her age (twenty-five) and marital status
(she married her high school sweetheart), there was an unspoken
assumption that had she not been stricken by this disease, Knapp would
have been a mother one day. The reader actually has no knowledge of the
Knapp’s plans for children, but the story seems deliberately written to stir
up those ideas. Young children like Jack Fowler and Josh Hardy fall in a
separate, tragic-yet-engrossing category of patients saddled with the burden
of deadly diseases at heartbreaking and unfairly young ages.183
The final factor that unites many of these individuals is affluence.
There are two types of affluence at work here: the traditional monetary type
and the social capital type.184 Social capital is the “collective value of all
‘social networks’ [who people know] and the inclinations that arise from
these networks to do things for each other [‘norms of reciprocity’].”185

178. See Merck & Bristol-Myers Squibb: Save Locky’s Dad: Provide Nick Auden access to the
PD1 drug on a compassionate basis, CHANGE.ORG,https://www.change.org/p/merck-bristolmyers-squibb-save-locky-s-dad-provide-nick-auden-access-to-the-pd1-drug-on-a-compassionatebasis (last accessed on Apr. 28, 2016) (collecting 525,739 signatures in support of Auden’s cause).
See also SAVE LOCKY’S DAD, http://www.savelockysdad.com/ (last accessed on Apr. 28, 2016).
179. Save Locky’s Dad, YOUTUBE, (Aug. 28, 2013), https://youtu.be/3teA62o5eLY.
180. Mikaela Conley, After YouTube Plea, Dying Mom Clears Hurdles to Start Trial Drug
Pertuzumab Friday, ABC NEWS (Apr. 26, 2012), http://abcnews.go.com/Health/youtube-pleadying-mom-clears-hurdles-start-trial/story?id=16224371.
181. See Kroll, supra note 161.
182. Id.
183. See Persad et al., supra note 176, at 425 (suggesting that another way to think about
allocating medical resources is to give them to younger people, because saving their lives at a
young age would create the maximum benefit).
184. About Social Capital, HARVARD KENNEDY SCHOOL: THE SAGUARO SEMINAR,
http://www.hks.harvard.edu/programs/saguaro/about-social-capital (last visited Sept. 23, 2015).
185. Id.
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Many studies suggest that there is some degree of racial inequity in social
capital as well.186 Some of the aforementioned compassionate use seekers
have financial affluence; for example, Nick Auden’s website describes him
as a successful businessman.187 Auden also had the resources to design an
entire website for his cause, including a well-produced YouTube video.188
Regardless of their actual socioeconomic status, all of the parties were able
to leverage their social capital to help boost their social media presence and
traditional media coverage. Josh Hardy had the support of a lawyer to help
lobby media outlets to carry his story.189 Before her cancer diagnosis,
Mikaela Knapp had a career in public relations, and many of her former
colleagues helped leverage their social capital, including connections to
journalists, to spread her story.190
Social justice concerns are also raised by DTC medical research
products and apomediation because there is less control over who uses the
products to contribute to medical research. First, to take advantage of
products like applications developed with Apple ResearchKit, users have to
be able to afford the compatible Apple equipment, such as an iPhone.191
Because the types of people that utilize these apps to participate in studies
are likely to be more affluent, the resulting research may not be
generalizable to more diverse populations.192 Similarly, this holds true for
any company that uses data generated from PGT kits that consumers
purchase. These items are not covered by medical insurance and are a
luxury item that large segments of the population cannot afford.193 For
186. Rodney E. Hero, Social Capital and Racial Inequality in America, 1 PERSP. ON POLITICS
113, 113–22 (2003).
187. Save Locky’s Dad, SAVE LOCKY’S DAD (March 2014), http://www.savelockysdad.com/.
188. Id.
189. See Richard Plotkin, Live or Let Die: Who Makes the Hard Decisions, MAX CURE
FOUND., https://maxcurefoundation.org/liveorletdie/ (last visited Sept. 23, 2015) (detailing retired
trial lawyer Richard Plotkin’s successful attempt to secure the necessary drug for Josh Hardy). It
is interesting to note that after that event, Plotkin has joined with Chimerix supervisor Moch to
advocate for a better system to handle this type of resource allocation, in part because Plotkin had
to turn down a number of other families requesting his help after his national public success
working on behalf of the Hardy family and realized there was no obvious way to choose who to
help and who to turn away. Id.
190. See Kroll, supra note 161.
191. See Buy iPhone 6, APPLE, http://www.apple.com/shop/buy-iphone/iphone6 (last accessed
on Apr. 28, 2016) (selling the current version of the iPhone for $549 or $649 for the iPhone 6 Plus
version, which has a slightly larger screen).
192. See Brandon Bailey, Software Turns Smartphones Into Tools For Medical Research, AP
(July 27, 2015), http://bigstory.ap.org/article/1a59a2e8e6e1478697c1fdabeacf7a04/software-turnssmartphones-tools-medical-research (noting that iPhone users tend to be more affluent, therefore
studies conducted via this medium might not “accurately mirror” the larger population).
193. See Jim Edwards, Still Don’t Believe Android Is For the Poor? This Chart Proves It,
BUSINESS INSIDER (Aug. 15, 2014) http://www.businessinsider.com/android-iphone-marketshare-by-price-2014-8 (arguing that Android phones are generally bought by people with lower
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example, 23andMe sells their test kit for ninety-nine dollars.194 This kit is
marketed as a product that helps people determine their genetic ancestry
and then allows consumers to indicate if they are willing to have their
results also used for research purposes.195
Similarly, patients who are using apomediation to design research
studies run the risk of creating participant pools that lack diversity. By
recruiting via word of mouth, patients rely on their social networks to
attract patients to their studies. While this could address the problem of
chronically slow enrollment in research studies, it also creates problems
because the majority of people do not have diverse networks of friends.196
A 2013 survey of social media habits revealed that 75 percent of white
Americans have entirely white social networks.197 The figures are similar,
though not as drastic for people of other racial backgrounds. For example,
65 percent of black Americans report having exclusively black friend
groups.198 With the reality that many Americans have segregated networks,
relying so heavily on referring friends could lead to heavily skewed results
that do not account for the actual diversity of the patient population.
Even websites such as PatientsLikeMe acknowledge bias in their data
sets.199 They note that their users are slightly younger, more likely to be
female, and are better educated than the general population.200
PatientsLikeMe has taken steps to try to account for these differences by
over-sampling patients who self-identify with underrepresented
demographics.201 Still, researchers and scientists should be working to
actively recruit and assist patients who are less educated, older, and more
racially diverse while employing new technology in the research sphere.

incomes because of their significantly lower price point and that Apple’s iPhone is geared toward
the upper end of the market).
194. 23ANDME, www.23andMe.com (last visited Apr. 1, 2016).
195. Id.
196. See Daniel Cox et al., Analysis: Race and Americans’ Social Networks, PUB. RELIGION
RES. INSTIT., http://publicreligion.org/research/2014/08/analysis-social-network (last visited Sept.
24, 2015) (reporting on the social homogeneity of social networks based on self-report).
197. Id.
198. Id. (observing also that 46 percent of Hispanic Americans have entirely homogenous
social networks).
199. Isn’t
Your
Data
Biased?,
PATIENTSLIKEME
HELP
CENTER,
https://support.patientslikeme.com/hc/en-us/articles/202224430-Isn-t-your-data-biased
(last
visited Sept. 25, 2015).
200. Id. (comparing PatientsLikeMe populations to databases such as organ transplant
registries, insurance claims data, and specialist centers focused on particular diseases).
201. Id.
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B. Resource Allocation and Access Issues

Ken Moch, the CEO of Chimerix described his concerns with the Josh
Hardy situation in terms of resource allocation.202 As he put it, he was
concerned not just about Josh, but the “many Joshes”: all of the patients
who were not famous but who suffered from similar conditions and would
benefit from his company’s product if it got approval for widespread
sale.203 Difficult decisions about resource allocation are made more
challenging by adding an emotional layer to the appeal.204 It is easier to
make a decision about who lives and who dies when just considering
figures and data on a sheet of paper, rather than connecting with patients on
a personal level. In the realm of soliciting donations to charity, academics
have called this the “identifiable victim” phenomenon.205 When faced with
a prospective candidate, people can often be swayed to make irrational
choices if given relatable and identifiable information.206 However, when
those irrational choices impact the allocation of a finite resource, this can
lead to particularly unfair results, in light of the social justice concerns
described above.207 There is a utilitarian argument in forgoing
compassionate use altogether in order to maximize the positive impact of
getting the drug to market quickly. Since compassionate use campaigns
divert resources from the main study, they can severely slow down the
research needed to get the drug to the broadest range of beneficiaries.208
Yet, over the last few decades, people have demanded a compassionate use
option so a balance must be found with addressing the needs of very ill
patients who advocate for themselves and the needs of present and future
patients who cannot advocate for themselves.

202. Caplan & Moch, supra note 1.
203. Id.
204. See To Increase Charitable Donations, Appeal to the Heart — Not The Head, WHARTON
SCH.
OF
BUS.
AT
THE
UNIV.
OF
P A.
(June
27,
2007),
http://knowledge.wharton.upenn.edu/article/to-increase-charitable-donations-appeal-to-the-heartnot-the-head/ (reporting that charities often make emotional appeals, particularly by describing in
detail one particular recipient to make the problem more relatable to potential donors).
205. See id. (detailing the difference between the identifiable victim and what the study called
the statistical victim: one or a group only known by their numerical or data characteristics).
206. See Deborah A. Small et al., Sympathy and Callousness: The Impact of Deliberative
Thought on Donations to Identifiable and Statistical Victims, 102 ORGANIZATIONAL BEHAVIOR &
HUMAN DECISION PROCESS 143 (2007) (arguing that people do not “value lives consistently”
when making charitable donations).
207. See id. (suggesting that collectively society would benefit from distributing resources
more rationally by donating money to the places it would have the largest impact).
208. Cf. Caplan & Moch, supra note 1 (arguing that smaller companies are particularly illpositioned to meet the demands of a compassionate use program and still maintain regular
operations).
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C. Deterioration of the Doctor Patient Relationship
Both DTC products and apomediation threaten the doctor-patient
relationship. This special relationship is built on trust and has been
described as the “keystone of care” because the primary means by which a
doctor provides care is through talking to and observing the patient while
communicating medical information to them.209 Patients who are directly
engaged with their providers have better care outcomes and are more
satisfied with their healthcare experience.210 Despite all of the welldocumented benefits of a strong doctor-patient relationship, apomediation
and DTC products do not typically involve doctors, or at most, involve
them peripherally.211 For example, DTC products take traditional medical
or genetic testing and allow people to conduct those tests on themselves.212
While this may give users more autonomy, it essentially denies them the
benefit of an expert interpreting all of the resulting data, unless they take
the extra step of bringing their purchased data to a medical professional.213
In particular, supplying genetic tests without the support of a medical
professional raises concerns because these tests are rarely entirely
conclusive and may not always be accurate.214 Rather, genetic sequencing
can reveal some information about the statistical likelihood of developing a
certain condition—subject to interpretation.215 Many genetic conditions are
the result of a variety of genetic factors and that might not be clear to a
209. See Susan Dorr Goold & Mark Lipkin, Jr., The Doctor-Patient Relationship: Challenges,
Opportunities, and Strategies, 12 J. GEN INTERN MED. S26 (1999) (listing different
responsibilities of the relationship, such as diagnosing the patients, ensuring compliance with
treatments, engaging and healing the patient, and providing support).
210. See id. (observing that a successful doctor-patient relationship also increases provider
satisfaction and prevents burn-out).
211. See Misti Crane, Dispatch Special Report: Bypassing Doctors, THE COLUMBUS
DISPATCH
(Dec.
11,
2012,
6:17
AM),
http://www.dispatch.com/content/stories/local/2012/12/11/bypassing-doctors.html
(recounting
that, at the time the article was published, there were twenty companies offering genetic testing
without physician involvement).
212. Id.
213. See id. (suggesting that without experts to interpret the data, people “can be misled, scared
or given false reassurances that prompt them to make bad decisions,” though some companies also
offer access to genetic counselors).
214. See id. (recalling one patient, who saw ultimately saw a doctor after a 23andMe genetic
test indicated he was at higher risk for esophageal cancer, found out that risk was based on a study
conducted on a small population in China that was not applicable to a Caucasian male living in
Ohio). See also Dina F. Maron, What Rare Disorder Is Hiding In Your DNA?, SCIENTIFIC
AMERICAN (Jan. 1, 2015), http://www.scientificamerican.com/article/what-rare-disorder-ishiding-in-your-dna/ (noting that genetic tests are not always conclusive).
215. See Maron, supra note 214 (reporting that in 2013, the American College of Medical
Genetic and Genomics suggested that results should be returned from fifty-six genes tested by
comprehensive tests because there was enough information that particular mutations associated
with those genes “met a standard of relatively high likelihood of being disease-causing”).
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consumer based on the information they receive from an at-home test kit.216
Further, many of these results could merit follow-up with a medical
provider but users may feel unsure of which doctor to go to with questions,
if they choose to seek one out at all.217 These DTC products could be
helpful if patients use them to have a dialogue with the provider, but are
potentially dangerous if people rely exclusively on these for-profit tests to
glean important medical information about themselves. Doctors are legally
and ethically required to always act in consideration of the patient’s best
interest and well-being. A for-profit company and its executives have a
fiduciary duty to investors or shareholders and their primary responsibility
is to make money. This is not conducive to helping patients sort through
complex medical information or make important health care decisions.
D. Jeopardizing the Quality of Science
Concerns abound regarding the quality of the medical research
produced by these new products and procedures. Crowdsourcing
compassionate use decisions can impact the quality of science because
recipients may not fit into the strict criteria of studies approved by the FDA,
yet the FDA will still consider how the drug impacts these patients when
deciding to approve additional or continuing research.218 Based on the
urgency of the compassionate use patients that need a particular drug,
pharmaceutical companies are forced to temporarily suspend many of the
hallmarks of reputable scientific process.219 These patients are not a part of
double-blind studies with placebos and control groups, nor are they
carefully selected based on the narrow criteria that allow scientists to
accurately evaluate the drug’s efficacy.220 Recipients of compassionate use
are typically already dying, so if they receive the drug and die anyway, it is
nearly impossible to determine what role the drug played in that event.221
216. See Rachael Rettner, 23andMe: What’s Really Wrong with Personal Genetic Tests,
LIVESCIENCE (Nov. 26, 2013, 1:55 PM), http://www.livescience.com/41534-23andme-direct-toconsumer-genetic-test-shortcomings.html (observing that many factors, including genetic markers
not tested by kits like 23andMe, contribute to the development of any single disease).
217. See id. (noting that companies like 23andMe offer to connect patients to genetic
counselors, but it unclear how many follow-up on that offer).
218. See Gaffney, supra note 5 (noting that an incident that occurs with a patient in a
compassionate use program could cause the FDA to prevent the product from reaching the
market).
219. See id. (suggesting that companies might not want to participate in compassionate use
because it would mean “letting products out of tightly controlled and heavily monitored
environments, potentially subjecting the product to incorrect use and previously unknown adverse
events”).
220. Id.
221. See id. (noting that to be eligible for the program, patients must have serious or
immediately life-threatening diseases).
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Compassionate use cases are not quality research, yet the FDA considers
the outcomes in these cases when determining if trials should continue.222
Even if they do not ultimately impact the quality of research performed,
they slow down the process significantly and prevent promising new drugs
from reaching the market sooner.223
In the last few years, the FDA has increasingly scrutinized PGT
companies over concerns that the products that they sell do not produce
accurate scientific results.224 The increased pressure has caused many
companies to stop marketing their DNA sequencing tests to the public.225
While these types of companies may have a legitimate interest in attempting
to further medical innovation, they are still at their core for-profit
businesses and are vulnerable to similar financial pressures as
pharmaceutical companies. Financial concerns often create a conflict with
the pursuit of quality scientific work and may lead companies to make false
claims about the capabilities of their products in order to sell a few more
units.226
23andMe is one of these direct-to-consumer PGT businesses that has a
long history of struggling with the FDA.227 The company started
negotiating with the agency in 2009 and continued for years before the talks
deteriorated in 2013.228 23andMe stopped participating in the talks while
simultaneously launching a national ad campaign with the goal of having
one million users purchase their ninety-nine dollar test kit.229 23andMe
produced a commercial that heralded the tests supposed ability to tell users
hundreds of things about their health, but the FDA intervened and issued a
warning letter demanding that 23andMe stop airing the ad until their genetic
testing had been proven to actually provide accurate information regarding
consumers health.230 The FDA also expressed concerns that the test could

222. Id.
223. Id.
224. See Andrew Pollack, FDA Orders Genetic Testing Firm to Stop Selling DNA Analysis
Service, N.Y. TIMES, Nov. 25, 2013 (reporting on a letter the FDA sent to one company ordering
them to halt public sales of their genetic testing kit).
225. Id.
226. See Kira Lerner, 23andMe Faces Suit Over Recently Banned DNA Tests, LAW360 (Jan.
22, 2014), http://www.law360.com/articles/502855/23anzdme-faces-suit-over-recently-banneddna-tests (describing a lawsuit alleging that 23andMe embellished their product’s capabilities to
increase sales).
227. George J. Annas & Sherman Elias, 23andMe and the FDA, 370 NEW ENG. J. MED. 985,
985–88 (2014).
228. Id. at 985.
229. Id.
230. See Warning Letter from Alberto Gutierrez, Director of the Office of In Vitro Diagnostics
and Radiological Health at the Center for Devices and Radiological Health, U.S. Food & Drug
Admin.,to
Ann
Wojcicki,
CEO
of
23andMe,
Inc.
(Nov.
22,
2013),
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lead users to take drastic action regarding potential health concerns, which,
given that the test kit was not validated, could be particularly dangerous to
patients.231 As a result of the warning letter, 23andMe stopped marketing
their test kit as a health product, and marketed the product only on its ability
to provide users information about their genealogy and their raw genetic
data.232 23andMe was no longer able to provide customers with interpretive
information about their genetic data, including health risks, drug responses,
and inherited conditions.233
Apomediation may also compromise the quality of science by failing
to utilize all of the safeguards developed over time to protect patients. The
ALS study run by users on PatientsLikeMe was not subject to any of the
usual research requirements such as submitting plans to an Institutional
Review Board to ensure that subjects are not at risk.234 IRB requirements
have developed out of necessity because in the past doctors have taken
advantage of these special relationships and performed inappropriate tests
on unknowing patients.235 Though this could still occur today, it would be
more difficult for a doctor to escape notice because of the amount of
requirements that must be adhered to before conducting research,
particularly on human subjects.236
Especially since the 1970s, when the Belmont Report was published
by the National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research, the medical and ethical communities
have attempted to hold their members to certain standards of practice and
provide avenues to hold them legally accountable when those principles are
http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm376296.htm (exuding
obvious frustration with the company for not fully responding to FDA requests).
231. See id. (noting that the risk of a false positive is that patients will begin to pursue a variety
of potentially invasive screening and prevention methods for a particular disease that are
“morbidity-inducing actions” and that a false negative could provide users with a false sense of
security that would prevent them for seeking potentially life-saving early intervention measures).
232. See
FDA
Update:
December
5th,
23ANDME
(Dec.
5,
2013),
https://customercare.23andme.com/hc/en-us/articles/202908030-FDA-Update-December-5th
(offering customers who purchased the kit in the time between the FDA’s letter and this
announcement a full refund as they could no longer provide the services that had been advertised).
233. Id.
234. See O’Connor, supra note 137, at 473 (stating that an IRB was not required because it was
conducted without receiving any federal funding).
235. See Margaret R. Moon & Felic Khin-Maung-Gyi, The History and Role of Institutional
Review Boards, 11 VIRTUAL MENTOR, 311 (2009) (recalling historical horrors such as the
Tuskegee Syphilis Study or the Willowbrook study of hepatitis in intellectually disabled children,
both examples of studies conducted without the patients’ knowledge or consent which ultimately
prompted regulation on research in the United States).
236. See Ethical Guidelines & Regulations, NAT’L INSTS. OF HEALTH, RESEARCH INVOLVING
HUMAN SUBJECTS (Feb. 5, 2016), https://humansubjects.nih.gov/ethical-guidelines-regulations,
(noting that in addition to ethical guidelines, both the Department of Health and Human Services
and the FDA have regulations designed to protect human research subjects).
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violated.237 Patient groups are not required to submit their research designs
to anyone.238 If someone in the PatientsLikeMe ALS research had gotten
hurt because of the study, they would have no clearly identifiable avenue of
recourse.239 Individual people operating without oversight do not have to
provide informed consent agreements, or to explain how they intend to use
the collected data.240 They could also, intentionally or unintentionally,
mislead patients into participating in something that is either dangerous or
promises benefits that cannot be substantiated.241 Good science protects the
consumer, and supporters of apomediation have not satisfactorily addressed
the lack of oversight inherent in a process without traditional medical
infrastructure. Supporters have suggested that patients who participate in
apomediated studies are more willing to undergo greater risk because they
are more likely to personally gain from the results.242 However, there still
might be people who are willing to take advantage of that willingness and
convince others to engage in a harmful study or practice, under the guise of
advancing science.243 Dangerous research without certain procedures to
minimize risk should be viewed critically.

237. See NAT’L COMM’N FOR THE PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL &
BEHAVIORAL RES., THE BELMONT REPORT 1–7 (1979) (articulating the guiding principles for
human subjects research, which include respect for persons, beneficence, and justice).
238. O’Connor, supra note 137.
239. See Lauren Solbert, Regulating Human Subjects Research in the Information Age: Data
Mining on Social Networking Sites, 39 N. KY. L. REV. 327, 354 (noting that it is unclear how
federal law covers entities like PatientsLikeMe where users have very different expectations than
those engaging in traditional research and accept more risk when they join the site).
240. See O’Connor, supra note 137 (stating that studies formed by individual patients, with no
connection to federal funding sources, operate outside of the boundaries Common Rule, which
requires informed consent). See also Federal Policy for the Protection of Human Subjects
(‘Common Rule’), U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES (Mar. 18, 2016),
http://www.hhs.gov/ohrp/regulations-and-policy/regulations/common-rule/index.html (explaining
that the Common Rule outlines provisions for IRBs and informed consent).
241. See Jef Akst, Do-It-Yourself-Medicine, THE SCIENTIST (Mar. 1, 2013), http://www.thescientist.com/?articles.view/articleNo/34433/title/Do-It-Yourself-Medicine/ (noting that many
ALS patients joined the PatientsLikeMe study because of promising results from a study using
lithium in Italy, but even though lithium is approved for other uses in the U.S., the drug could
interact in different, unforeseen ways with this patient population and actually harm them).
242. See id. (quoting Richard Bedlack, director of the Duke University ALS Clinic, who while
discussing this new form of what he calls DIY research programs, stated “I don’t think anybody
has more to gain or lose from all than patients”).
243. See Colleen C. Denny & Christine Grady, Clinical Research With Economically
Disadvantaged Populations, 33 J. MED. ETHICS 382, 383 (2007) (recounting how economically
disadvantaged patients may be so desperate for the potential benefits of a study, such as access to
medical treatments or free healthcare, that they will ignore risks and participate in the study no
matter what, leading to questions about the ethics of that research).
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IV. ADDRESSING THE PROBLEMS
A. Crowdsourcing

There is no fair and ethical way that crowdsourcing can be used in the
compassionate use context. Crowdsourcing the decision about which
musical artist should get a record deal and other lighthearted popular culture
decisions may work, but the same technique should not be applied to an
ethically complex and technical medical decision. While giving power to
the people is generally a commendable action, at some points the general
population is not in the best position to determine who gets a valuable,
finite resource. Since the news coverage of Joshua Hardy’s request for
compassionate use was so skewed, it is reasonable to suggest that the
average person who signed an online petition or sent an email did not know
all of the factors Chimerix had to balance. If many members of the general
population do not take the time to become informed voters in a presidential
election campaign held once every four years, it is both unreasonable and
unrealistic to think the same population could ever be informed about the
small, yet critical, details that are associated with the hundreds of people
that request compassionate use.244 The FDA should prohibit companies
from considering such campaigns when making decisions and provide an
alternative structure.
The FDA cannot simply instruct pharmaceutical companies to ignore
crowdsourced compassionate use campaigns because the companies could
still be influenced by their shareholders and stock prices; therefore, a new
structure needs to be established. One solution is to create a new
organization, be it a government agency or a private entity, to review and
allocate compassionate use resources.245 This entity should be funded by
each pharmaceutical company, which would contribute money based on the
size of their business and the number of their clinical trials under review by
the FDA.246 For example, Merck and other behemoths of the
pharmaceutical industry should contribute a greater amount of funds than a
small start-up like Chimerix. Companies should factor this into the cost of
bringing a drug to market. The money would be used to not only staff this
entity but to support the cost of actually providing a drug for compassionate

244. See Steve Chapman, Mixing Ignorance and Democracy: Can Our System Work with
Uninformed Voters?, CHICAGO TRIBUNE, Apr. 19, 2012 (lamenting the fact that most voters will
not make the effort to learn even the most basic facts of most candidates running for election).
245. See Caplan & Moch, supra note 1 (suggesting that an organization independent of
pharmaceutical companies needs to be created, but not suggesting whether such an entity should
be a government undertaking something unaffiliated with the federal government).
246. But see id. (suggesting that the public, presumably through government taxes, might fund
compassionate use since the people are demanding such a program).
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use, thus eliminating the need for companies to divert additional resources
from clinical trials. The entity would then have the responsibility for
reviewing all compassionate use requests and not just approving them, like
the FDA currently does, but also allocating the resources. The entity— and
not the pharmaceutical company—would then be in the position of making
the difficult decision of denying a requested drug. This entity and
pharmaceutical companies would work together to determine how many
patients could feasibly receive a given drug at any stage of development.
This model would share some similarities with the way organ donations,
another finite medical resource, are allocated.247 There are only two
ethically appropriate ways for the general population to be more broadly
involved in the compassionate use context. First, crowdsourcing could be
translated into crowdfunding to help bolster the compassionate use
program.248 Second, crowdsourcing could be used to help find the
necessary patients to fill studies quickly and get the drugs to mass market
faster.249
B. Direct-to-Consumer
In February 2015, the FDA announced that they would authorize
23andMe to market a product that would inform healthy adults if they
possessed a genetic variant that would increase their odds of their children
having Bloom Syndrome.250 More broadly, the FDA also stated their intent
to exempt all carrier screening test devices from premarket review by the

247. See
Organ
Allocation,
UNITED
NETWORK
FOR
ORGAN
SHARING,
http://www.unos.org/donation/index.php?topic=organ_allocation (last visited Sept. 25, 2015)
(describing how UNOS prioritizes patients for organ donations by considering a variety of factors
including match and recipient urgency, geography, and how long a recipient had been waiting.
UNOS does not factor in “celebrity status.”).
248. See Gaffney, supra note 5 (attributing part of pharmaceutical companies’ hesitancy in
participating in compassionate use to the financial burdens of fulfilling requests).
249. See E-Recruiting: Using Digital Platforms, Social Media, and Mobile Technologies to
Improve
Clinical
Trial
Enrollment,
INVENTIVE
HEALTH
(Oct.
14,
2013),
http://www.inventivhealth.com/docs/eRecruiting_Using_Digital_Platforms_Social_Media_and_Mobile_Technologies_to_Improve_Clin
ical_Trial_Enrollment.pdf (advising pharmaceutical companies to identify key opinion leaders,
such as bloggers who could support trial participation, or post in patient-led online community
groups to boost trial enrollment).
250. FDA Permits Marketing of First Direct-To-Consumer Genetic Carrier Test for Bloom
Syndrome,
U.S.
FOOD
&
DRUG
ADMIN.
(Feb.
19,
2015),
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435003.htm; See also
Bloom Syndrome, U.S. NAT’L LIBR. OF MED.: GENETICS HOME REFERENCE (Apr. 2015),
http://ghr.nlm.nih.gov/condition/bloom-syndrome (describing Bloom syndrome as a genetic
disorder marked by “short stature, sun-sensitive skin changes, an increased risk of cancer, and
other health problems).
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agency, pending a thirty-day period for public comment.251 This represents
a compromise between the FDA, which is responsible for ensuring that
consumers get accurate information from healthcare products, and
companies like 23andMe that advocate for broader, if not total, consumer
access to genetic information.252 To secure this approval, 23andMe went
through a rigorous process to ensure the accuracy of this specific test, its
replicability across a wide number of laboratories, and the intelligibility of
the accompanying literature provided to consumers.253 23andMe does not
intend to market their test for Bloom Syndrome yet, instead choosing to
wait until they have completed the “regulatory process” for additional
carrier tests so that they can market a more comprehensive testing
package.254
Commentators observe that this is a small step that is likely to lead to
future acceptance of broader availability of genetic sequencing.255
23andMe and the FDA have laid the framework for safely marketing these
products in the future. However, there is still a large difference between
providing a test that screens for a few specific carrier genes and marketing a
product that provides a complete genetic sequence. Ultimately, users should
have access to their genetic information if they desire it, just like patients
have a right to their medical records and other test results generated by
doctors.256 Attempts to address this issue must take into consideration
consumer autonomy.257 However, we have agencies such as the FDA in
order to protect consumers from companies, because consumers are often
unable to question the effectiveness of a product or understand all of the

251. See id. (stating that such action created “the least burdensome regulatory path for
autosomal recessive carrier screening tests with similar uses to enter the market”).
252. See David Kroll, FDA Approves 23andMe Gene Carrier Test, FORBES (Feb. 19, 2015),
http://www.forbes.com/sites/davidkroll/2015/02/19/fda-okays-23andmes-direct-to-consumergene-carrier-testing-starting-with-bloom-syndrome/.
253. 23andMe Granted Authorization by FDA to Market First Direct-to-Consumer Genetic
Test Under Regulatory Pathway for Novel Devices, 23ANDME (Feb. 19, 2015),
http://www.prnewswire.com/news-releases/23andme-granted-authorization-by-fda-to-marketfirst-direct-to-consumer-genetic-test-under-regulatory-pathway-for-novel-devices300038925.html.
254. Id.
255. See Kroll, supra note 252 (observing that “choosing autosomal recessive gene traits for
exemption from premarketing approval gives the FDA more time to discern how they will manage
direct-to-consumer gene testing where the results have short- or long-term impact on the person
being tested”).
256. See Abena Yeboa, What Is the Future For Genetic Testing and Personalized Medicine,
PENN PROGRAM ON REG. (Feb. 6, 2014), http://www.regblog.org/2014/02/06/06-yeboapersonalized-medicine/ (noting that this is an area of considerable debate).
257. See id. (noting that consumers want full access to genetic testing services but still wanted
some protection in the form of government oversight).
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science a device, test, or drug employs.258 The biggest concern is making
sure that users understand the information that they receive, particularly if it
indicates that they are at risk for a genetic condition.
There are three possible ways the DTC market could develop. First,
companies could be given free rein to sell their products to consumers.
While this gives users the most autonomy to access their genetic
information, it is also the most likely to lead to the lowest quality science.
This approach seems unlikely given that the FDA has already gotten so
involved with the issue. The second and more restrictive way would be to
retreat from the DTC approach and have these products available through
licensed professionals only, such as doctors or genetic counselors.259 While
some tests that are available to consumers at home, such as a pregnancy
test, the vast majority of medical screening is still done in the traditional
healthcare setting.260 This theoretically ensures that patients have
professional interpretation of their results. However, market demand and
regulatory trends indicate that backtracking in this direction is also
unrealistic.261 As the FDA has already started to demonstrate, the ethical
approach moving forward should be somewhere in between these two
extremes. When the FDA approved 23andMe’s at home test for Bloom’s
Syndrome, they required the labeling to explain what the results of the test
might mean for users.262 Further, if these products were sold over the
counter, the FDA would also require the company to inform consumers

258. See How Can Consumers Be Sure a Genetic Test is Valid and Useful?, GENETICS HOME
REFERENCE:
U.S.
NAT’L
LIBRARY
OF
MED.
(Apr.
26,
2016),
https://ghr.nlm.nih.gov/primer/testing/validtest (noting that patients might have a difficult time
determining the quality of at home genetic testing, particularly if the company providing the test
are not certified under federal laboratory standards).
259. See About Genetic Counselors, NAT’L SOC’Y OF GENETIC COUNSELORS,
http://nsgc.org/p/cm/ld/fid=175 (last visited Apr. 24, 2015) (noting that genetic counselors have
specialized graduate degrees that they use interpret genetic data both from tests and family
histories).
260. See Home Use Tests, U.S. FOOD & DRUG ADMIN. (June 5, 2014)
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/HomeUs
eTests/, (cataloging the ten types of currently approved home-use diagnostic tests, including tests
for pregnancy, ovulation, and HIV). See also Mary K. Caffrey, FDA Moves to Regulate
Thousands of Diagnostic Tests, AM. J. MANAGED CARE (Aug. 25, 2014),
http://www.ajmc.com/journals/evidence-based-oncology/2014/august-2014/fda-moves-toregulate-thousands-of-diagnostic-tests (noting that there are thousands of diagnostic tests).
261. See Testing for HIV, U.S. FOOD & DRUG ADMIN. (Aug. 8, 2013),
http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/HIVHomeTestKits/ucm126460.h
tm (describing the availability of FDA approved test-kits that allow users to test for HIV at home,
which shows that the direct-to-consumer market is expanding to include diagnostic tests for
serious conditions).
262. FDA Permits Marketing of First Direct-To-Consumer Genetic Carrier Test for Bloom
Syndrome, supra note 250 (noting that some people might be better served by tests, but that the
agency would not limit who should or should not use the test).
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about professionals—in this case, a board-certified clinical molecular
geneticist or equivalent—that could provide pre- and post-test
counseling.263 This type of counseling was already suggested by some of
the companies that produce PGT products, but had never been prominently
advertised.264Having this counseling advertised in conjunction with the
marketing of the product is critical. Because it seems these companies are
driven by collecting profitable banks of genetic data rather than by
providing individual patients the data they need to make better health care
decisions, counseling has thus far been an afterthought.
The FDA should also be closely monitoring the informed consent
documents associated with both using these products for testing and,
separately, allowing genetic information to be stored in a data bank and
used or sold for future research. One possibility would be to have users
provide a general consent for future research studies, but notify them of
new uses periodically and allow them to remove their information if they no
longer wish to participate.265 The burden should be on the companies to
maintain contact about the latest studies, not forcing consumers to seek out
that information. Companies should maintain information on their websites
about all of the studies that are currently in progress using data collected
from their products. Another idea would be to limit private companies’
ability to wholesale databanks of genetic information to third parties. Rather
than having a private buyer just buy a database, researchers and other
companies should be required to have a specific proposal for how they
intend to use the data and a legal obligation to refrain from using the
information for other purposes. The selling company should also have to
provide information about third party studies to consumers as well, along
with the pertinent contact information to the third party if the individual
263. See id. (implying that the burden is on consumers to decide if they want to follow-up on
their results with a professional).
264. See 23andMe Carrier Status Tests: What You Should Know, 23ANDME,
https://www.23andme.com/carrierstatus-fda/ (last accessed on Apr. 29, 2016) (recommending that
patients contact the National Society of Genetic Counselors to find a professional near them that
can help them decide if certain genetic testing for carrier traits is “right for” the patient). This
information is available by clicking a link labeled “Important Info: Carrier Status Reports” on the
main purchasing page for the company, though the purchasing page itself does not mention
genetic counseling. Id.
265. See David R. Karp, et al., Ethical and Practical Issues Associated with Aggregating
Databases, PLOS MED (Sept. 23, 2008), http://dx.doi.org/10.1371/journal.pmed.0050190
(offering alternative ways to navigate the ethical concerns of informed consent for research when
data is collected and the future uses are unknown, including the possibility of providing future
updates regarding findings). The proposals suggested in this paper call for a much greater degree
of specificity and a greater burden on the company collecting data to provide information about
potential studies on an ongoing basis. Karp acknowledges that one cannot truly give informed
consent to unspecified actions that might occur in the future, and since informed consent is a
cornerstone of research ethics, this paper argues that more specific steps are necessary.
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wishes to withdraw their information because of the nature of a particular
study.
Finally, even if they are not legally required to, companies should
work harder to increase the diversity of the population using their products.
Whether through donations, grants, or other fundraising mechanisms,
companies should actively strive to make sure their products are used by
people from varied racial, ethnic, and socioeconomic backgrounds. This
could mean getting test kits into public health departments, or partnering
with local non-profits to create a distribution program for low-cost
smartphones preloaded with data collection apps.
C. Apomediation
Since apomediation is not under the purview of the traditional
regulations that oversee research and protect participants, the responsibility
falls to the publisher of studies to ensure that the data collected meets the
same quality standards that would be required of traditional research.
Further, if researchers worked more in conjunction with patients, as
envisioned by the Affordable Care Act, the scientific and medical
community could gain the benefits of apomediation without the potential
for poorly conducted science.266 Patients should be able to suggest what
illnesses and conditions should be researched and researchers should be
reaching out to patients groups to develop hypotheses based on the
experiences, concerns, and suggestions of the patients. This is where social
media and even DTC products could be extremely valuable. Using products
like Apple’s ResearchKit will give researchers more insight into the daily
experiences of people suffering from a variety of conditions and should
influence the course of future study.267 Rather than full apomediation, the
goal should not be to remove the traditional intermediary, but rather to
include the patient in the conversation in an equal capacity with doctors,
researchers, and other professionals. While researchers can certainly learn
more from their patients, the professionals contribute a level of technical

266. 111 P.L. 148, 124 Stat. 119.
267. See, e.g., Ian Paul, Stanford’s ResearchKit App Gained More Users in 24 Hours Than
Most Medical Studies Find in a Year, MACWORLD (Mar. 12, 2015),
http://www.macworld.com/article/2895941/stanfords-researchkit-app-gained-more-users-in-24hours-than-most-medical-studies-find-in-a-year.html (recounting how over 11,000 people signed
up to participate in a Standford study about heart health on the first day, a feat that would
normally take researchers about a year to accomplish). See also Caitlin McGarry, ResearchKit at 6
Months: 100,000 People Now Using Medical Apps, MACWORLD (Oct. 15, 2015),
http://www.macworld.com/article/2993838/ios/researchkit-at-6-months-100-000-people-nowusing-medical-apps.html (demonstrating that patients have been very interested in using the apps,
new apps, studying conditions such as autism, melanoma, and epilepsy were recently released, and
while still a new product, researchers are optimistic about the products ability to impact science).
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expertise and objectivity that patients themselves may lack. Additionally,
by including professionals who are subject to a variety of oversight, from
licensing boards to federal agencies, there is some avenue of recourse if
these professionals do not meet legal and ethical standards. Medical
research has an unfortunate history of abuse and apomediated research
could be just as dangerous without any of the safeguards that have been
developed for traditional medicine.
V. CONCLUSION
There has always been tension between pursuing medical innovation
and developing laws and policies that ensure breaking developments stay
within ethical bounds. In that regard, Medicine 2.0 is no different from its
early predecessors. While modern technology has allowed for many
important advancements, it also demands further scrutiny to determine if
every new product or concept is actually something that improves health
outcomes and patient experiences. New technology can be so appealing that
it may distract users from unaddressed ethical issues. Rather than just
allowing these new technologies to grow unchecked, it is important to
question innovation and find ways to incorporate new technologies into our
societal norms and ethical expectations.

